Literature DB >> 9112576

Multiple urinary cytokine levels of bacterial cystitis.

R Davidoff1, R Yamaguchi, G E Leach, E Park, P M Lad.   

Abstract

PURPOSE: We have examined urinary cytokine levels to define the inflammatory response in patients with bacterial cystitis or microhematuria relative to normal subjects. Cytokines examined include interleukin-1beta (IL-1beta), IL-1alpha, tumor necrosis factor (TNF alpha), IL-6 and IL-4. Unique features of this study include a) a simultaneous study of several relevant cytokines b) a study of the inflammatory response at both low and high counts of bacterial infection and c) an assessment of whether microhematuria without bacterial cystitis or pyuria is associated with cytokine elevation compared to normals.
MATERIALS AND METHODS: Enzyme immunoassays were utilized for each cytokine. Patients studied include those with bacterial cystitis (n = 49), patients with microhematuria (n = 11), and normal subjects (n = 36). Cytokine levels were also determined for patients with low count bacterial cystitis (1,000-50,000 organisms; n = 15) and compared to high count bacterial cystitis (>100,000 organisms; n = 34) and normal subjects. Statistical analysis was carried out using the Kruskal-Wallis test followed by pairwise testing with Newman-Keuls test.
RESULTS: a) The means for normal, microhematuria and bacterial cystitis groups were significantly different (p <0.05) for IL-1beta, IL-1alpha, TNF alpha and IL-6, but not for IL-4. b) Except for IL-4, all cytokines were found to be significantly elevated in low count bacterial cystitis compared to normals. No statistically significant difference was observed between low and high count bacterial cystitis groups for any of the cytokines tested.
CONCLUSIONS: a) Significant and similar inflammatory responses are present in both low and high count bacterial cystitis groups as compared with the normal group. b) IL-6 and TNF alpha are significantly elevated in patients with microhematuria compared to normals. c) The potential clinical utility of the assays lies in identifying the specific cytokines elevated, understanding the pathways that give rise to their production, and in defining potential virulence factors that may produce significant inflammation at low count bacterial infections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9112576

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Elevated urinary cytokine levels in patients undergoing ileal neobladder replacement compared with sigmoid neobladder replacement.

Authors:  Yuzo Nakano; Hideaki Miyake; Taka-Aki Inoue; Atsushi Takenaka; Isao Hara; Masato Fujisawa
Journal:  Int Urol Nephrol       Date:  2007-02-20       Impact factor: 2.370

2.  Is there a relation between urinary interleukin-6 levels and symptoms before and after intra-vesical glycosaminoglycan substitution therapy in patients with bladder pain syndrome/interstitial cystitis?

Authors:  Lukas K Daha; Dara Lazar; Reiner Simak; Heinz Pflüger
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-03-20

3.  [The disturbing development of resistance in urinary tract infections].

Authors:  C Hampel; R Gillitzer; S Pahernik; J W Thüroff
Journal:  Urologe A       Date:  2002-12-20       Impact factor: 0.639

4.  Prospective cohort study of microbial and inflammatory events immediately preceding Escherichia coli recurrent urinary tract infection in women.

Authors:  C A Czaja; W E Stamm; A E Stapleton; P L Roberts; T R Hawn; D Scholes; M Samadpour; S J Hultgren; T M Hooton
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

5.  Levels of inhibitors of tumor necrosis factor alpha and interleukin 1beta in urine and sera of patients with urosepsis.

Authors:  D P Olszyna; J M Prins; B Buis; S J van Deventer; P Speelman; T van der Poll
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

6.  Genetic control of the variable innate immune response to asymptomatic bacteriuria.

Authors:  Jenny Grönberg-Hernández; Jenny Grönberg Hernández; Fredrik Sundén; John Connolly; Catharina Svanborg; Björn Wullt
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

7.  Pannexin 1 involvement in bladder dysfunction in a multiple sclerosis model.

Authors:  Hiromitsu Negoro; Sarah E Lutz; Louis S Liou; Akihiro Kanematsu; Osamu Ogawa; Eliana Scemes; Sylvia O Suadicani
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

8.  Development of an interstitial cystitis risk score for bladder permeability.

Authors:  Laura E Lamb; Joseph J Janicki; Sarah N Bartolone; Kenneth M Peters; Michael B Chancellor
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

9.  Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women.

Authors:  Thomas R Hawn; Delia Scholes; Hongwei Wang; Sue S Li; Ann E Stapleton; Marta Janer; Alan Aderem; Walter E Stamm; Lue Ping Zhao; Thomas M Hooton
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

10.  Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy.

Authors:  Hsin-Tzu Liu; Yuan-Hong Jiang; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.